Boca generic version of Tapazole cleared by FDA
Florida, USA-based privately-held Boca Pharmacal said on Friday that it has received approval from the Food and Drug Administration for its Abbreviated New Drug Application for methimazole tablets USP, 5mg and 10mg, the generic version of King Pharmaceuticals' Tapazole, which is indicated for the treatment of hyperthyroidism.
"This is our first approval this year and we are expecting a second before the end of the first quarter," said Robert Edwards, chief executive of Boca Pharmacal, adding: "As our pipeline continues to mature and we come to the end of our largest development cycle, Boca expects to have multiple approvals this year."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze